Literature DB >> 18406942

Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials.

Geoffrey S Ibbott1, David S Followill, H Andrea Molineu, Jessica R Lowenstein, Paola E Alvarez, Joye E Roll.   

Abstract

The Radiological Physics Center (RPC) has functioned continuously for 38 years to assure the National Cancer Institute and the cooperative groups that institutions participating in multi-institutional trials can be expected to deliver radiation treatments that are clinically comparable to those delivered by other institutions in the cooperative groups. To accomplish this, the RPC monitors the machine output, the dosimetry data used by the institutions, the calculation algorithms used for treatment planning, and the institutions' quality control procedures. The methods of monitoring include on-site dosimetry review by an RPC physicist and a variety of remote audit tools. The introduction of advanced technology clinical trials has prompted several study groups to require participating institutions and personnel to become credentialed, to ensure their familiarity and capability with techniques such as three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, stereotactic body radiotherapy, and brachytherapy. The RPC conducts a variety of credentialing activities, beginning with questionnaires to evaluate an institution's understanding of the protocol and their capabilities. Treatment-planning benchmarks are used to allow the institution to demonstrate their planning ability and to facilitate a review of the accuracy of treatment-planning systems under relevant conditions. The RPC also provides mailable anthropomorphic phantoms to verify tumor dose delivery for special treatment techniques. While conducting these reviews, the RPC has amassed a large amount of data describing the dosimetry at participating institutions. Representative data from the monitoring programs are discussed, and examples are presented of specific instances in which the RPC contributed to the discovery and resolution of dosimetry errors.

Entities:  

Mesh:

Year:  2008        PMID: 18406942      PMCID: PMC2409281          DOI: 10.1016/j.ijrobp.2007.08.083

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Dosimetric considerations for validation of a sequential IMRT process with a commercial treatment planning system.

Authors:  P Cadman; R Bassalow; N P S Sidhu; G Ibbott; A Nelson
Journal:  Phys Med Biol       Date:  2002-08-21       Impact factor: 3.609

2.  Credentialing of institutions for IMRT in clinical trials.

Authors:  Jatinder R Palta; James A Deye; Geoffrey S Ibbott; James A Purdy; Marcia M Urie
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

3.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.

Authors:  Mark J Rivard; Bert M Coursey; Larry A DeWerd; William F Hanson; M Saiful Huq; Geoffrey S Ibbott; Michael G Mitch; Ravinder Nath; Jeffrey F Williamson
Journal:  Med Phys       Date:  2004-03       Impact factor: 4.071

4.  Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group.

Authors:  Andrea Molineu; David S Followill; Peter A Balter; William F Hanson; Michael T Gillin; M Saiful Huq; Avraham Eisbruch; Geoffrey S Ibbott
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

Review 5.  Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.

Authors:  Jeffrey F Williamson; Wayne Butler; Larry A Dewerd; M Saiful Huq; Geoffrey S Ibbott; Michael G Mitch; Ravinder Nath; Mark J Rivard; Dorin Todor
Journal:  Med Phys       Date:  2005-05       Impact factor: 4.071

Review 6.  Intensity-modulated radiation therapy for gynecologic cancers: pitfalls, hazards, and cautions to be considered.

Authors:  Marcus E Randall; Geoffrey S Ibbott
Journal:  Semin Radiat Oncol       Date:  2006-07       Impact factor: 5.934

7.  Independent evaluations of IMRT through the use of an anthropomorphic phantom.

Authors:  Geoffrey S Ibbott; Andrea Molineu; David S Followill
Journal:  Technol Cancer Res Treat       Date:  2006-10

8.  Dose specification and quality assurance of radiation therapy oncology group protocol 95-17; a cooperative group study of iridium-192 breast implants as sole therapy.

Authors:  Geoffrey S Ibbott; W F Hanson; Elizabeth O'Meara; Robert R Kuske; Douglas Arthur; Rachel Rabinovitch; Julia White; Raymond M Wilenzick; Irene Harris; Ramesh C Tailor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-01       Impact factor: 7.038

9.  Design, development, and implementation of the radiological physics center's pelvis and thorax anthropomorphic quality assurance phantoms.

Authors:  David S Followill; DeeAnn Radford Evans; Christopher Cherry; Andrea Molineu; Gary Fisher; William F Hanson; Geoffrey S Ibbott
Journal:  Med Phys       Date:  2007-06       Impact factor: 4.071

  9 in total
  44 in total

1.  Toward a better understanding of the gamma index: Investigation of parameters with a surface-based distance method.

Authors:  Heng Li; Lei Dong; Lifei Zhang; James N Yang; Michael T Gillin; X Ronald Zhu
Journal:  Med Phys       Date:  2011-12       Impact factor: 4.071

2.  The effect of slice thickness on target and organs at risk volumes, dosimetric coverage and radiobiological impact in IMRT planning.

Authors:  S P Srivastava; C-W Cheng; I J Das
Journal:  Clin Transl Oncol       Date:  2015-08-27       Impact factor: 3.405

3.  A comprehensive evaluation of the PRESAGE/optical-CT 3D dosimetry system.

Authors:  H S Sakhalkar; J Adamovics; G Ibbott; M Oldham
Journal:  Med Phys       Date:  2009-01       Impact factor: 4.071

4.  Investigation of the feasibility of relative 3D dosimetry in the Radiologic Physics Center Head and Neck IMRT phantom using presage/optical-CT.

Authors:  Harshad Sakhalkar; David Sterling; John Adamovics; Geoffrey Ibbott; Mark Oldham
Journal:  Med Phys       Date:  2009-07       Impact factor: 4.071

5.  Design and implementation of a "cheese" phantom-based Tomotherapy TLD dose intercomparison.

Authors:  Hans Schiefer; Konrad Buchauer; Simon Heinze; Guido Henke; Ludwig Plasswilm
Journal:  Strahlenther Onkol       Date:  2015-06-19       Impact factor: 3.621

6.  Examining credentialing criteria and poor performance indicators for IROC Houston's anthropomorphic head and neck phantom.

Authors:  Mallory E Carson; Andrea Molineu; Paige A Taylor; David S Followill; Francesco C Stingo; Stephen F Kry
Journal:  Med Phys       Date:  2016-12       Impact factor: 4.071

7.  Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance.

Authors:  Justin E Bekelman; James A Deye; Bhadrasain Vikram; Soren M Bentzen; Deborah Bruner; Walter J Curran; James Dignam; Jason A Efstathiou; T J FitzGerald; Coen Hurkmans; Geoffrey S Ibbott; J Jack Lee; Thomas E Merchant; Jeff Michalski; Jatinder R Palta; Richard Simon; Randal K Ten Haken; Robert Timmerman; Sean Tunis; C Norman Coleman; James Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-15       Impact factor: 7.038

8.  Credentialing results from IMRT irradiations of an anthropomorphic head and neck phantom.

Authors:  Andrea Molineu; Nadia Hernandez; Trang Nguyen; Geoffrey Ibbott; David Followill
Journal:  Med Phys       Date:  2013-02       Impact factor: 4.071

9.  Development of a novel treatment planning test for credentialing rotational intensity-modulated radiotherapy techniques in the UK.

Authors:  Y Tsang; L Ciurlionis; C Clark; K Venables
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

10.  Radiation therapy quality assurance in clinical trials--Global Harmonisation Group.

Authors:  Christos Melidis; Walter R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Satoshi Ishikura; David Followill; James Galvin; Ying Xiao; Martin A Ebert; Tomas Kron; Catharine H Clark; Elizabeth A Miles; Edwin G A Aird; Damien C Weber; Kenneth Ulin; Dirk Verellen; Coen W Hurkmans
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.